AI-Discovered Drug for Idiopathic Pulmonary Fibrosis Enters Late-Stage Clinical Trials

Artificial intelligence is helping the world find new drug treatments, and a leading company is about to reach an important milestone by moving an algorithm‑discovered drug into late‑stage trials. The company, Insilico Medicine, headquartered in Hong Kong and New York, is using AI to develop a drug for an incurable lung disease, idiopathic pulmonary fibrosis.

The drug is currently undergoing mid‑stage clinical trials in the United States and China, with preliminary results expected in early 2025. The trial has attracted great attention in the pharmaceutical industry because Insilico not only used AI to identify a new approach to combat this deadly disease but also developed a novel molecule for treatment. Deep Pharma Intelligence in the UK noted that Insilico’s drug is the world’s first fully AI‑discovered pre‑clinical candidate.

Insilico’s founder and CEO Alex Zhavoronkov said the breakthrough was possible because the company “used AI to find a new target, discovered a molecule, and has entered mid‑stage clinical trials.” He added that if the lung disease drug succeeds, “it will change everything.”